Several factors account for expanded interest in investigating HRR alterations in PCa: the high frequency of HRR mutations in multiple cancers including PCa21 combined with the knowledge that there is a significantly higher risk of developing PCa with BRCA2 mutation (8.6×) and the fact that BRCA2 mutation is more commonly found in patients with PCa.25 PARPi has shown clinical benefits in PCa, breast cancer,26 and ovarian cancer,27 and more clinical trials are currently ongoing (Tables 1 and 2). This evidence concerns the gene BRCA2 and breast cancer.